Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.

White JB, Fleming R, Masterson L, Ruddle BT, Zhong H, Fazenbaker C, Strout P, Rosenthal K, Reed M, Muniz-Medina V, Howard P, Dixit R, Wu H, Hinrichs MJ, Gao C, Dimasi N.

MAbs. 2019 Apr;11(3):500-515. doi: 10.1080/19420862.2019.1578611. Epub 2019 Mar 5.


Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses.

Chen B, Vousden KA, Naiman B, Turman S, Sun H, Wang S, Vinall LMK, Kemp BP, Kasturiangan S, Rees DG, Grant E, Hinrichs MJ, Eck S, DiGiandomenico A, Jack Borrok M, Ly N, Xiong X, Gonzalez C, Morehouse C, Wang Y, Zhou Y, Cann J, Zhao W, Koelkebeck H, Okubo K, Mayadas TN, Howe D, Griffiths J, Kolbeck R, Herbst R, Sims GP.

Ann Rheum Dis. 2019 Feb;78(2):228-237. doi: 10.1136/annrheumdis-2018-213523. Epub 2018 Nov 20.


Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.

Hinrichs MJM, Ryan PM, Zheng B, Afif-Rider S, Yu XQ, Gunsior M, Zhong H, Harper J, Bezabeh B, Vashisht K, Rebelatto M, Reed M, Ryan PC, Breen S, Patel N, Chen C, Masterson L, Tiberghien A, Howard PW, Dimasi N, Dixit R.

Clin Cancer Res. 2017 Oct 1;23(19):5858-5868. doi: 10.1158/1078-0432.CCR-17-0219. Epub 2017 Jun 19.


Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.

Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, Bannister D, Jovanovic J, Fleming R, D'Hooge F, Mao S, Marrero AM, Korade M 3rd, Strout P, Xu L, Chen C, Wetzel L, Breen S, van Vlerken-Ysla L, Jalla S, Rebelatto M, Zhong H, Hurt EM, Hinrichs MJ, Huang K, Howard PW, Tice DA, Hollingsworth RE, Herbst R, Kamal A.

Mol Cancer Ther. 2017 Aug;16(8):1576-1587. doi: 10.1158/1535-7163.MCT-16-0825. Epub 2017 May 18.


Interpreting and Integrating Clinical and Anatomic Pathology Results.

Ramaiah L, Hinrichs MJ, Skuba EV, Iverson WO, Ennulat D.

Toxicol Pathol. 2017 Jan;45(1):223-237. doi: 10.1177/0192623316677068. Epub 2016 Nov 14. Review.


Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.

Thompson P, Fleming R, Bezabeh B, Huang F, Mao S, Chen C, Harper J, Zhong H, Gao X, Yu XQ, Hinrichs MJ, Reed M, Kamal A, Strout P, Cho S, Woods R, Hollingsworth RE, Dixit R, Wu H, Gao C, Dimasi N.

J Control Release. 2016 Aug 28;236:100-16. doi: 10.1016/j.jconrel.2016.06.025. Epub 2016 Jun 18.


A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR.

Cancer Cell. 2016 Jan 11;29(1):117-29. doi: 10.1016/j.ccell.2015.12.008. Erratum in: Cancer Cell. 2019 Jun 10;35(6):948-949.


Antibody Drug Conjugates: Nonclinical Safety Considerations.

Hinrichs MJ, Dixit R.

AAPS J. 2015 Sep;17(5):1055-64. doi: 10.1208/s12248-015-9790-0. Epub 2015 May 30. Review.


Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.

Hansen AR, Cook N, Ricci MS, Razak A, Le Tourneau C, McKeever K, Roskos L, Dixit R, Siu LL, Hinrichs MJ.

Oncologist. 2015 Jun;20(6):653-9. doi: 10.1634/theoncologist.2015-0008. Epub 2015 May 11.


Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.

Ryan PC, Sleeman MA, Rebelatto M, Wang B, Lu H, Chen X, Wu CY, Hinrichs MJ, Roskos L, Towers H, McKeever K, Dixit R.

Toxicol Appl Pharmacol. 2014 Sep 1;279(2):230-9. doi: 10.1016/j.taap.2014.06.002. Epub 2014 Jun 15.

Supplemental Content

Loading ...
Support Center